The rare disease space is experiencing remarkable growth, propelled by advancements in technology, regulatory incentives such as accelerated approval pathways, heightened funding and investment, robust patient advocacy and collaborative initiatives. Xtalks spoke with Richard Philipson, MD, Chief Medical Officer (CMO) at Calliditas Therapeutics, a Sweden-based company with full commercial operations in the US focused on […]